Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 2Meningioma 2Medulloblastoma 2Malnutrition 2Lung Neoplasms 1Liver Neoplasms 1Liver Failure 1Hyperphagia 1Hyperinsulinism 1Hematologic Neoplasms 1Fibrosis 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × Amino Acids × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT03013387 2017-08-25

Dosimetry Guided PRRT With 90Y-DOTATOC

University of Iowa

Phase 2 Withdrawn
CNS

Medulloblastoma, Meningioma, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡